ASH 2010 Conference Coverage

Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL

ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.

Primary Care Physicians May Be Key to Meeting the Growing Demand for Cancer Care

Radical improvements in diagnostic services, cancer education, and training, and policies that encourage integration between primary and specialist care, primary care doctors could hold the key to meeting the growing demand for cancer care.

Half-Match Donors May be the Perfect Match In Transplantation for Blood Cancers

Bone marrow transplantation is a life-saving treatment for many people with blood cancers such as leukemia and lymphomas.

Gay, Bisexual Men Report Higher Rates of Skin Cancer Than Heterosexual Men

Gay and bisexual men indoor tan more frequently and report higher rates of skin cancer than heterosexual men.

Fukushima Radiation May Be Increasing Pediatric Thyroid Cancer Rates

Children living near the Fukushima nuclear meltdowns in Japan have a much higher rate of thyroid cancer diagnoses than that of children elsewhere.

Targeted Online Advertising May Effectively Deliver Skin Cancer Prevention Education

Online targeted advertising based on Google search terms may be an effective way to deliver targeted skin cancer prevention education.

DNA Alterations Occur the Earliest in Lung Cancer Development

Working with tissue, blood, and DNA from six people with precancerous and cancerous lung lesions, scientists identified what they believe are the very earliest premalignant genetic changes that mark the potential onset of lung cancer.

Study Reveals New Driver for Assessing Cancer Survival and Drug Sensitivity

Cancer specialists have long looked at genetic mutations and DNA copy changes to predict patient survival and drug sensitivity. A study has opened up yet another avenue for understanding why some people live longer or respond better to treatment.

Older Patients with Hodgkin Lymphoma Benefit from Treatment with Brentuximab Vedotin

Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.

Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma (RCC).

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs